Bubs' record quarter amid Chinese demand
Australian baby formula producer Bubs is enjoying improved sales despite the coronavirus pandemic and has reported its highest quarterly gross revenue.
Steven Deare
Australian Associated PressApril 15, 20209:35am
Australian baby formula producer Bubs has reported its highest quarterly gross revenue thanks to booming demand in China for infant formula.
Bubs' $19.7 million revenue for the quarter ended March 31 was helped by sales in China more than doubling on the same period last year.
Chief executive Kristy Carr said production of goat milk infant formula had been prioritised, with sales of that product up by 137 per cent on a year ago.
Despite the coronavirus pandemic, there has been minimal disruption to production and supplying overseas customers, Ms Carr said.
Total sales in Australia increased by 34 per cent, helped by supplying about 200 Woolworths stores with infant formula in March.
The formula will be supplied to about 700 of the stores by May.
Bubs' year-to-date gross revenue is $48.5 million - already more than its 2019 full year revenue of $46.8 million.
Mr Carr said direct sales to China had doubled and there was strong demand in Vietnam.
Bubs in February reported a $7.5 million first half net loss, although this was better than the $8.8 million loss for first half 2019.
The improving results have helped its share price avoid the sharp plunge of many others during the pandemic.
Since the start of the year, Bubs shares have fallen 11.22 per cent in value to 87 cents before trade opened on Wednesday.
This compares favourably to a 17.89 per cent wider market drop.
- Forums
- ASX - By Stock
- BUB
- Ann: FY20 Q3 Activities Report and Appendix 4C Cashflow Statement
BUB
bubs australia limited
Add to My Watchlist
5.56%
!
17.0¢

Ann: FY20 Q3 Activities Report and Appendix 4C Cashflow Statement, page-37
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $151.8M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.0¢ | $170.5K | 979.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 716290 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 97636 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 645650 | 0.170 |
7 | 369412 | 0.165 |
14 | 400986 | 0.160 |
23 | 1360110 | 0.155 |
23 | 1338487 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 47636 | 5 |
0.180 | 912370 | 19 |
0.185 | 226700 | 6 |
0.190 | 481314 | 13 |
0.195 | 322491 | 6 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
BUB (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online